Business
Bruce Binkowitz Joins Arcutis as Vice President of Biometrics
WESTLAKE VILLAGE, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"WESTLAKE VILLAGE, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Bruce Binkowitz has joined as Vice President of Biometrics. Dr. Binkowitz, who brings over 30 years of drug development experience, will lead all biometrics activities for the company including supporting late-stage clinical programs and regulatory submissions of topical roflumilast in psoriasis, atopic dermatitis, and seborrheic dermatitis. “We are pleased to welcome Bruce to Arcutis. He is an experienced leader who will play an instrumental role as we advance multiple pivotal clinical studies and our upcoming submission of our first New Drug Application for roflumilast cream,” said Frank Watanabe Arcutis’ President and Chief Executive Officer. “Arcutis is making a real difference by advancing novel treatments for serious skin disorders where little progress has been made in decades,” Dr. Binkowitz said. “I am excited to join the experienced medical and regulatory team and further clinical programs across our seven therapeutic areas.” Most recently, Dr. Binkowitz was the Vice President of Biometrics at Shionogi, Inc., after spending over 30 years at Merck and Co. He has worked across all phases of drug development and across many therapeutic areas including dermatology, oncology, respiratory, metabolism/diabetes, cardiovascular and ophthalmology. Dr. Binkowitz has presented at all the major statistics conferences and has publications spanning more than 30 years, including his contributions as a thought leader on the topic of multiregional clinical trials. Dr. Binkowitz is a Fellow of the American Statistical Association (ASA), and was the 2020 Chair and is current Past-Chair of the Biopharmaceutical Section of the ASA. Dr. Binkowitz has a Ph.D. in Quantitative Methodology from the Rutgers School of Public Health, and a Master’s degree in Statistics from the University of Florida. About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological disea...